Details

Autor(en) / Beteiligte

• Grosso, Dolores A.
• Hess, Rosemary C.
• Weiss, Mark A.

Titel

Immunotherapy in acute myeloid leukemia

Ist Teil von

• Cancer, 2015-08, Vol.121 (16), p.2689-2704

Ort / Verlag

United States

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Despite the remarkable progress made in some leukemias such as CML and CLL, cytotoxic treatment for AML remains essentially unchanged over the last 4 decades. Several lines of evidence, including the graft versus leukemia effect associated with allogeneic hematopoietic stem cell transplantation (HSCT), suggest that immunotherapy is an active modality in AML. Given the lack of progress for chemotherapy in this disease, many novel immunologic treatment approaches have been explored. The goals of non‐transplant‐based immune approaches have largely consisted of the stimulation or restoration of endogenous immune responses or the targeting of specific tumor antigens by immune cells. These strategies have been associated with less toxicity than allogeneic HSCT but typically have inferior efficacy. Allogeneic HSCT exploits major and minor histocompatibility differences between the donor and recipient in order to recognize and eradicate malignancy. With the recognition that the immune system itself provides a basis for treating AML, immunotherapy continues to be an attractive modality to exploit in the treatment of this disease. Cancer 2015;121:2689‐2704. © 2015 American Cancer Society The authors review immunologic strategies that have been used in the treatment of acute myeloid leukemia. Areas addressed include transplantation and nontransplantation immunologic approaches to acute myeloid leukemia treatment as well as newer therapies, such as chimeric antigen receptors and bispecific T‐cell engagers.